Given that Ptpn2 sgRNA depletion is only seen in the in vitro screen condition in which anti-mCD19 CAR-T cells were added, these data suggest that mCD19-mediated release of IFNγ from anti-mCD19 CAR-T cells can exert anti-tumor activity in our in vitro screen conditions. The gene discussed is IFNG; the disease is neoplasm.